NEW YORK, June 30, 2016 /PRNewswire/ --

On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Cempra Inc. (NASDAQ: CEMP), and Hemispherx Biopharma Inc. (NYSEMKT: HEB). Learn more about these stocks by accessing their free trade alerts at:

http://stock-callers.com/registration

Agenus Inc., an immuno-oncology Company, focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer. The stock finished Wednesday's session 2.32% higher at $3.97 with a total volume of 729,417 shares traded. The stock is trading above its 50-day moving average by 2.59%. Agenus's stock has a Relative Strength Index (RSI) of 49.49. The Company was founded in 1994 and is headquartered in Lexington, Massachusetts. Sign up and read the free notes on AGEN at:

http://stock-callers.com/registration/?symbol=AGEN BioCryst Pharmaceuticals Inc., a biotechnology Company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The stock advanced 3.56% to close the day at $2.91 with a total volume of 481,707 shares traded. The stock is trading 8.11% below its 50-day moving average. Additionally, BioCryst Pharmaceuticals' stock has an RSI of 44.11. The Company was founded in 1986 and is headquartered in Durham, North Carolina. The complimentary notes on BCRX can be downloaded in PDF format at: http://stock-callers.com/registration/?symbol=BCRX On Wednesday, shares in Cempra Inc. ended the session 1.60% higher at $16.54 with a total volume of 615,657 shares traded. The clinical-stage pharmaceutical Company focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. The stock is trading 5.39% below its 50-day moving average. Moreover, shares of Cempra have an RSI of 38.00. The Company was founded in 2005 and is headquartered in Chapel Hill, North Carolina. Register for free on Stock-Callers.com and access the latest research on CEMP at:

http://stock-callers.com/registration/?symbol=CEMP On Wednesday, shares in Hemispherx Biopharma Inc. ended the day 2.38% higher at $0.12 with a total volume of 555,117 shares traded. The specialty pharmaceutical Company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The stock is trading below its 50-day moving average by 5.67%. Furthermore, shares of Hemispherx Biopharma have an RSI of 45.11. The Company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania. Get free access to your trade alert on HEB at:

http://stock-callers.com/registration/?symbol=HEB

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com . Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer

        
         
        CONTACT 
        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        EmptyBreak:MARKER 
        Email: info@stock-callers.com 
        Phone number: +44 330 808 3765 
        Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2
         1BP 

 

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA